Darolutamide Potentiates the Antitumor Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC) by a Dual Mode-of-Action in Prostate Cancer Models

Researchers evaluated the efficacy and explored the mode-of-action of the PSMA-TTC BAY 2315497, an antibody-based targeted alpha therapy, in combination with the androgen receptor inhibitor darolutamide.